Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
Status:
Not yet recruiting
Trial end date:
2029-03-30
Target enrollment:
Participant gender:
Summary
The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and
piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the
safety of these two drugs is unclear in this group of patients.
Phase:
Phase 4
Details
Lead Sponsor:
Scandinavian Critical Care Trials Group
Treatments:
Meropenem Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam